Blockbuster RA drug wins FDA panel vote

In a near unanimous vote, an FDA expert committee has endorsed Roche's Actemra for approval for use against rheumatoid arthritis. The 10-1 vote moves the drug one more critical step closer to a likely FDA approval of a drug that is a serious contender for blockbuster status.

"Based on the strength of the data presented, and the positive recommendation by the committee, we are hopeful that the FDA will approve Actemra for the treatment of RA and provide a new option to patients who are not achieving adequate symptom relief with current therapies," said Kenneth Bahrt, M.D., Roche's global medical director, autoimmunity.

- read the press release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.